TOP > 外国特許検索 > BENZOTHIAZOLE COMPOUND AND MEDICINE CONTAINING SAME

BENZOTHIAZOLE COMPOUND AND MEDICINE CONTAINING SAME 新技術説明会

外国特許コード F170008962
整理番号 E112P06WO
掲載日 2017年3月13日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP070317
国際公開番号 WO 2016010092
国際出願日 平成27年7月15日(2015.7.15)
国際公開日 平成28年1月21日(2016.1.21)
優先権データ
  • 特願2014-145736 (2014.7.16) JP
発明の名称 (英語) BENZOTHIAZOLE COMPOUND AND MEDICINE CONTAINING SAME 新技術説明会
発明の概要(英語) Provided are: a compound that is useful as an amyloid oxidation catalyst which can be applied inside a living body and can be applied not only to Aβ peptides but also to other amyloids; and an amyloid-related preventive or therapeutic drug using said compound. A benzothiazole compound which is represented by general formula (1) (in the formula, X represents a halogen atom; R1 represents a hydrocarbon group which may have a substituent; R2 represents a hydrogen atom or a hydrocarbon group which may have a substituent; R3 and R4 are the same or different and represent a hydrogen atom, an alkoxy group, a halogen atom, an amino group, a nitro group, a cyano group, or a hydrocarbon group which may have a substituent; R2 and R4 together may form an alkylene group, and R5 represents an anion).
従来技術、競合技術の概要(英語) BACKGROUND ART
Usually, by folding of the protein, to form a specific native are responsible for vital functions, on the other hand misfolding rich fibers can be aggregated into β-sheet structure (amyloid-) sometimes. In the course of the production of the amyloid aggregates (oligomers, proto-fibrillar, fibers) known to cause various functions and disorders, (such conditions include 'amyloid' collectively referred to as a) one or more 20 of the amyloid protein have been identified as the causative agent of. Amyloid such as, for example, β amyloid Alzheimer's disease, tau protein, Parkinson's disease α-synuclein, amylin diabetes, systemic - cis transthyretin, such as Huntington's disease Huntingtin is known.
These pathogenic amyloid development of therapeutics targeting strategy include, for example Alzheimer's disease amyloid amyloid β (hereinafter referred to as A β) for, producing A β precursor protein from the enzyme inhibitor, accelerator A β-degrading enzyme, immunotherapy, and the like of the aggregation-inhibiting A β known. On the other hand, with respect to A β, oxidant Met A β peptide (A β peptide Met residues of the sulfur atom is oxidized with an oxidant (O) ) a small amount remains within the living body, and the agglomerates as compared to an oxidant may be Met A β peptide has been reported to have low (non-patent document 1-3). From such a viewpoint, the present inventors, represented by the formula flavin binding site A β photocatalyst A β A β peptide using the oxidation of a peptide in which the oxidant is obtained, the oxidant may be A β A β peptide reported to suppress the flocculation of (non-patent document 4).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • KANAI, Motomu
  • SOMA, Yohei
  • TANIGUCHI, Atsuhiko
  • SHIMIZU, Yusuke
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
参考情報 (研究プロジェクト等) ERATO KANAI Life Science Catalysis AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close